Drugs Made In America Acquisition (DMAA) Competitors $10.27 +0.01 (+0.10%) As of 07/25/2025 02:11 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock DMAA vs. USAR, SAFE, DEA, SBR, CSR, ORC, FBRT, NXRT, NOAH, and PAXShould you be buying Drugs Made In America Acquisition stock or one of its competitors? The main competitors of Drugs Made In America Acquisition include USA Rare Earth (USAR), Safehold (SAFE), Easterly Government Properties (DEA), Sabine Royalty Trust (SBR), Centerspace (CSR), Orchid Island Capital (ORC), Franklin BSP Realty Trust (FBRT), NexPoint Residential Trust (NXRT), Noah (NOAH), and Patria Investments (PAX). These companies are all part of the "trading" industry. Drugs Made In America Acquisition vs. Its Competitors USA Rare Earth Safehold Easterly Government Properties Sabine Royalty Trust Centerspace Orchid Island Capital Franklin BSP Realty Trust NexPoint Residential Trust Noah Patria Investments Drugs Made In America Acquisition (NASDAQ:DMAA) and USA Rare Earth (NASDAQ:USAR) are both small-cap trading companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation. Is DMAA or USAR more profitable? Drugs Made In America Acquisition's return on equity of 0.00% beat USA Rare Earth's return on equity.Company Net Margins Return on Equity Return on Assets Drugs Made In America AcquisitionN/A N/A N/A USA Rare Earth N/A -16.58%2.58% Which has higher valuation and earnings, DMAA or USAR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDrugs Made In America AcquisitionN/AN/AN/AN/AN/AUSA Rare EarthN/AN/A$7.90MN/AN/A Does the media favor DMAA or USAR? In the previous week, USA Rare Earth had 3 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 3 mentions for USA Rare Earth and 0 mentions for Drugs Made In America Acquisition. USA Rare Earth's average media sentiment score of 1.03 beat Drugs Made In America Acquisition's score of 0.00 indicating that USA Rare Earth is being referred to more favorably in the news media. Company Overall Sentiment Drugs Made In America Acquisition Neutral USA Rare Earth Positive Do analysts rate DMAA or USAR? USA Rare Earth has a consensus price target of $16.00, indicating a potential upside of 33.11%. Given USA Rare Earth's stronger consensus rating and higher possible upside, analysts plainly believe USA Rare Earth is more favorable than Drugs Made In America Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00USA Rare Earth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryUSA Rare Earth beats Drugs Made In America Acquisition on 6 of the 7 factors compared between the two stocks. Get Drugs Made In America Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAA vs. The Competition Export to ExcelMetricDrugs Made In America AcquisitionInvestment Offices IndustryFinancial SectorNASDAQ ExchangeMarket Cap$299.30M$166.73M$6.43B$9.50BDividend YieldN/AN/A4.19%4.01%P/E RatioN/AN/A14.0820.08Price / SalesN/AN/A1,726.2589.32Price / CashN/A36,857.63128.7158.56Price / BookN/AN/A1.965.88Net IncomeN/A-$160K$1.24B$258.89M7 Day PerformanceN/A0.35%0.50%3.71%1 Month PerformanceN/A1.36%3.27%11.72%1 Year PerformanceN/A5.59%25.52%18.01% Drugs Made In America Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMAADrugs Made In America AcquisitionN/A$10.27+0.1%N/AN/A$299.30MN/A0.002USARUSA Rare EarthN/A$12.30-3.5%$16.00+30.1%N/A$1.12BN/A0.00N/ASAFESafehold4.3108 of 5 stars$14.95-2.5%$22.33+49.4%-33.9%$1.07B$365.68M10.24120DEAEasterly Government Properties2.3665 of 5 stars$22.80-2.5%$27.15+19.1%-33.2%$1.02B$302.05M54.2850Positive NewsSBRSabine Royalty Trust1.9286 of 5 stars$66.32+0.2%N/A+3.1%$966.87M$83.17M12.442,020News CoveragePositive NewsCSRCenterspace1.9746 of 5 stars$57.68-1.4%$70.78+22.7%-16.8%$965.55M$260.98M-51.50470ORCOrchid Island Capital2.1795 of 5 stars$7.33-0.2%N/A-10.4%$928.15M$241.58M18.312,018News CoverageEarnings ReportAnalyst DowngradeFBRTFranklin BSP Realty Trust3.9472 of 5 stars$10.49-1.7%$15.13+44.2%-23.9%$862.05M$210.45M15.42N/APositive NewsUpcoming EarningsNXRTNexPoint Residential Trust4.8626 of 5 stars$33.77-2.3%$43.58+29.1%-20.7%$853.68M$259.70M-26.383Positive NewsUpcoming EarningsNOAHNoah3.0392 of 5 stars$12.48-0.4%$12.00-3.8%+60.6%$825.35M$356.33M12.861,990PAXPatria Investments2.7682 of 5 stars$13.53-1.0%$14.00+3.5%+6.3%$820.47M$390.10M27.06390News Coverage Related Companies and Tools Related Companies USAR Alternatives SAFE Alternatives DEA Alternatives SBR Alternatives CSR Alternatives ORC Alternatives FBRT Alternatives NXRT Alternatives NOAH Alternatives PAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Drugs Made In America Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Drugs Made In America Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
